A five year, post-marketing observational study to follow-up patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who are treated with HUMIRA (adalimumab)
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01078558?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
